Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Propanc Biopharma, Inc. announced corporate updates and year-end financial results for June 30, 2026. Key highlights include plans to initiate a world-first Phase 1b first-in-human clinical trial of its lead candidate PRP for advanced solid tumors in Q1 2027, progressing manufacturing and bio-analytical efforts, and securing over $7.5 million in fi…